Navigation Links
New treatment shows promise against recurrent gynecologic cancers
Date:4/21/2009

April 21, 2009 (BRONX, NY) Recurrent and metastatic endometrial and ovarian cancers can be notoriously difficult to treat: They have spread to other organs and typically have developed resistance to chemotherapy; and patients already heavily treated with chemotherapy may not be able to endure more chemo. Now, physicians at Albert Einstein College of Medicine of Yeshiva University have shown that a combination of two chemotherapy drugs not only produced clinical benefit for such patients but were also well tolerated. The findings are published online in the journal Gynecologic Oncology.

"Women with recurrent gynecologic cancers have often had multiple rounds of chemotherapy, which can cause tumor cells to develop resistance to these drugs," says Mark H. Einstein, M.D., associate professor of obstetrics & gynecology and women's health at Einstein, who headed the study. "This resistance can make it difficult for doctors to devise a treatment protocol that will impact the cancers while avoiding the often-severe side effects that certain chemotherapy drugs can cause, particularly when patients have already been heavily pretreated with other anti-cancer drugs."

In previous clinical studies, the chemotherapy drugs topotecan and docetaxel showed effectiveness when used separately against recurrent gynecologic cancers. The phase 2 trial conducted by Dr. Einstein and his colleagues─the first to evaluate the combination of the drugs for this purpose─involved 24 women with recurrent uterine, ovarian, fallopian or peritoneal cancers. The women were given the topotecan-docetaxel combination on Day 1 of the trial and then weekly for three weeks; after a one-week rest, the women received another three-week treatment cycle, ultimately undergoing six such treatment cycles.

Compared with previous clinical trials, an unusually high proportion of these women had been heavily pretreated with chemotherapy─yet nearly 40 percent of them experienced clinical benefit. In addition, the overall survival with the drug combination (median survival of 18.5 months) was higher than in previous phase 2 studies that evaluated the drugs when used singly. Finally, there were few and relatively mild side effects from the drug combination compared with toxicities observed in similar studies.

The trial's effectiveness and safety outcomes are "promising enough to justify a larger clinical study of this drug combination for women with recurrent gynecologic cancers," Dr. Einstein says.


'/>"/>

Contact: Deirdre Branley
dbranley@aecom.yu.edu
718-430-2923
Albert Einstein College of Medicine
Source:Eurekalert

Related medicine news :

1. Leading Critical Care Doctor Shifts From Treatment to Empowerment by Helping Americans Create Optimal Health in Their Lives
2. Surveyed Specialists Foresee Greater Use of Parenteral Outpatient Therapy for the Treatment of Osteomyelitis
3. Canadian Medical Device Set to Speed Treatment and Cut Health Care Costs for Common Cause of Vertigo
4. Mayo Clinic researchers formulate treatment combination lethal to pancreatic cancer cells
5. For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina)
6. Targeted Treatments Show Mettle Against Advanced Cancers
7. Treatment Algorithm Helps Successfully Manage Diabetes after Transplant Surgery
8. Dense Breasts Complicate Testing and Treatment
9. Medifocus Inc. Reports Improved Clinical Efficacy for its Phase II, Randomized Clinical Study for the Treatment of Early Stage Breast Cancer Tumors
10. Do patients at risk for B-cell malignancy need antiviral treatment?
11. Non-drug treatment of Alzheimers disease: Long-term benefit not proven
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/27/2017)... IL (PRWEB) , ... March 27, 2017 , ... ... systems, recently received the CE Certificate of Conformity for the Smart System® 20/20. ... or exceed the highest industry standards and specifications such as ANSI, ISO and ...
(Date:3/27/2017)... PA (PRWEB) , ... March 27, 2017 , ... ... business simulation -centric training, today announced the launch of a new research ... strategy, having the skills needed to execute that strategy, and the actual success ...
(Date:3/27/2017)... ... 2017 , ... According to the American Cancer Society , the average ... 95%. Once the cancer spreads to other organs, bones, or lymph nodes, however, the ... avoid this latter group, tune in to Lifestyle Magazine on April 9, ...
(Date:3/27/2017)... ... March 27, 2017 , ... ... facility from 8:00am-10:00am on Monday, April 3rd to commemorate the two-year anniversary of ... opportunity for area-residents to celebrate two great years while also familiarizing themselves with ...
(Date:3/25/2017)... ... March 25, 2017 , ... Getting earned media coverage meaningful ... partner. , All through the year, Garden Media aims to provide material helpful ... key influencers and pitching client’s key messages to gain coveted media placements, ...
Breaking Medicine News(10 mins):
(Date:3/27/2017)... 2017 BioLineRx Ltd. (NASDAQ/TASE: BLRX), a ... that AGI-134, an immunotherapy for the treatment of multiple cancers, ... be featured at the upcoming American Association for Cancer ... to be held on April 1-5, 2017. ... An abstract ...
(Date:3/27/2017)... 2017 The global clinical ... billion by 2025, according to a new study by ... diseases is anticipated to be responsible for the high ... the scope for growth during the forecast period. In ... is highly susceptible to chronic diseases, is presumed to ...
(Date:3/27/2017)... March 27, 2017  Impax Laboratories, Inc. (NASDAQ: IPXL)today ... Paul M. Bisaro as Impax,s President and Chief ... effective March 27, 2017. Mr. Bisaro will succeed ... President and Chief Executive Officer since December of 2016. ... branded pharmaceutical experience, Mr. Bisaro, 56, is an accomplished ...
Breaking Medicine Technology: